MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13506129.2024.2420809

Медицинская библиотека · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2024

PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study.

Suhr Ole B, Grogan Martha, Silva Ana Martins da, Karam Chafic, Garcia-Pavia Pablo, Drachman Brian, Zago Wagner, Tripuraneni Radhika, Kinney Gene G

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The investigational monoclonal antibody PRX004 is designed to specifically target and deplete TTR amyloid. Here, we report on the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of PRX004 in patients with ATTRv amyloidosis.

METHODS

This global, multicentre, phase 1 trial comprised a 3 + 3 dose-escalation phase and a long-term extension (LTE) phase (NCT03336580). In the dose-escalation phase, patients received PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months. In the LTE, eligible patients could receive up to 15 additional doses. Patients who received doses of ≥3 mg/kg for ≥9 months were assessed for Global Longitudinal Strain (GLS) and Neuropathy Impairment Score (NIS). The primary objective was to determine the maximum tolerated dose (MTD) of PRX004.

RESULTS

Overall, 21 patients with ATTRv amyloidosis completed the dose-escalation phase; 17 subsequently enrolled in the LTE. The MTD was not reached. PRX004 was well tolerated at all doses, with dose-proportional exposure. GLS and NIS were improved or maintained over 9 months (n = 7).

CONCLUSIONS

PRX004 was well tolerated in patients with ATTRv amyloidosis and demonstrated potential clinical activity. A phase 2 randomised controlled trial in ATTR cardiomyopathy is ongoing (NCT05442047).

Для цитирования: Suhr Ole B, Grogan Martha, Silva Ana Martins da, Karam Chafic, Garcia-Pavia Pablo, Drachman Brian, Zago Wagner, Tripuraneni Radhika, Kinney Gene G. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2024. DOI: 10.1080/13506129.2024.2420809.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.